Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

uniQure N.V. - Ordinary Shares (NQ:QURE)

16.47 +1.29 (+8.50%)
Streaming Delayed Price Updated: 1:13 PM EDT, Mar 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about uniQure N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
QURE Stock Edges Up After Hours As Analyst Flags Reduced Regulatory Uncertainty Following Prasad’s FDA Exit ↗
Mizuho said that Dr. Vinay Prasad’s exit just days after a highly public dispute with uniQure appeared to signal an administration-level desire to restore greater regulatory flexibility in rare disease... 
Via Stocktwits
News headline image
QURE Stock’s Relentless Rally Continues Today — Here's Why HC Wainwright Is Bullish On uniQure ↗
H.C. Wainwright stated that the reported departure of a key U.S. Food and Drug Administration official at the end of April bodes well for uniQure. 
Via Stocktwits
Topics Initial Public Offering
News headline image
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 ↗
Wells Fargo upgraded uniQure’s stock to ‘Overweight,’ citing a bullish outlook for its gene therapy following reports that Vinay Prasad will leave the U.S. FDA next month. 
Via Stocktwits
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
uniQure (NASDAQ:QURE) Stock Plummets 40% Despite Earnings Beat on FDA Setback for AMT-130 ↗
Via Chartmill
Topics Earnings
News headline image
Earnings Scheduled For November 10, 2025 ↗
 
Via Benzinga
News headline image
A Glimpse of uniQure's Earnings Potential ↗
 
Via Benzinga
News headline image
Biotech Stock QURE Once Tagged ‘Failed Product’ — CEO Sold Shares Days Before Rally ↗
On Friday, the trading volume for uniQure increased from its 2 million shares to roughly 17 million. 
Via Stocktwits
Here are the top movers in Friday's session. ↗
Via Chartmill
News headline image
These Analysts Cut Their Forecasts On uniQure Following Q4 Results ↗
uniQure (NASDAQ:QURE) reported positive Q4 results, but FDA advised against using data for market application of AMT-130. Stock down 13.3%. 
Via Benzinga
Iran, Dip-Buyers & a Rare Buffett Stumble: Wall Street Shakes Off Its Worst Fears ↗
Via Chartmill
Monday's session: top gainers and losers ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
uniQure (QURE) Q4 2025 Earnings Call Transcript ↗
uniQure (QURE) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Get insights into the top gainers and losers of Monday's pre-market session. ↗
Via Chartmill
News headline image
Why Did QURE Stock Almost Halve Pre-Market Today? ↗
uniQure said the FDA does not agree that Phase I/II data are sufficient to serve as primary evidence of effectiveness for a marketing application for its Huntington’s disease gene therapy, AMT-130. 
Via Stocktwits
News headline image
QURE Or RGNX: Which Gene Therapy Was FDA Chief Really Warning About In Rare Disease Remarks? ↗
Analysts are divided on the target, with RBC Capital and Stifel saying the comments appeared to reference uniQure, while Leerink argued they more closely align with Regenxbio’s RGX-121. 
Via Stocktwits
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
News headline image
FDA Commissioner Refers To Rare Disease Drug With Associated Morbidity: Analysts Are Divided If Makary Meant Regenxbio Or Uniqure’s Experimental Therapy ↗
Following the comments, shares of both Regenxbio and uniQure traded in the red. 
Via Stocktwits
Thursday's session: top gainers and losers ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market
The U.S. biotech sector has officially entered a new golden age. As of January 22, 2026, the industry is witnessing a "renaissance" that has effectively erased the memories of the grueling three-year... 
Via MarketMinute
Topics Artificial Intelligence ETFs Initial Public Offering
News headline image
uniQure Stock Jumps After Scheduling FDA Type A Meeting For AMT‑130 Approval Pathway ↗
uniQure N.V. (NASDAQ:QURE) shares are popping on Friday after the company said the FDA will review the data package for AMT‑130, its gene therapy for Huntington's disease, with a Type A meeting now... 
Via Benzinga
News headline image
What's going on in today's pre-market session ↗
Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Dow Jones Hits Record as Shutdown Deal Nears—AI Sector Feels the Heat ↗
Optimism about a possible end to the U.S. government shutdown pushed the Dow Jones to new highs, but Big Tech couldn’t keep up. Nvidia took a beating after SoftBank’s surprise exit. 
Via Chartmill
Topics Stocks
News headline image
uniQure (QURE) Q3 2025 Earnings Call Transcript ↗
uniQure (QURE) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Monday.Com, Metsera, Profrac Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally
The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
Biohaven Stock Hits 52-Week Low, Cuts R&D Spending After FDA Rejection ↗
Biohaven stock plunged after the FDA rejected Vyglxia for spinocerebellar ataxia, prompting major R&D cuts and a William Blair downgrade. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.